Different age, different phenotype: a comparative analysis of juvenile and adult-onset dermatomyositis from a tertiary center
Clicks: 1
ID: 325360
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #195 of 200 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 200 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Objectives To evaluate age-related differences in clinical features, serological profiles, diagnostic approaches, treatment strategies, and outcomes among juvenile- and adult-onset dermatomyositis (JDM and AoDM) patients managed at the same tertiary referral center. Methods This retrospective cohort included 180 patients with dermatomyositis meeting the 2017 EULAR/ACR classification criteria and followed between 1995 and 2025 at the pediatric and adult rheumatology clinics. Diagnosis before 16 years was classified as JDM. Results Among 180 patients, 86 had JDM and 94 had AoDM. A bimodal age distribution was observed, with peaks at 6.8 and 45.7 years. 67.8% were female; median follow-up was 5.9 years. Muscle weakness (86.7%) and cutaneous involvement (98.3%) were most common findings. Calcinosis was frequent in JDM (33%) but rare in adults (one case). Both calcinosis and arthritis were significantly associated with JDM (p = 0.007 and p = 0.049). Anti-NXP2 was the leading JDM autoantibody (31.4%, 11/35), whereas anti-synthetase antibodies (34.6%, 9/26) in AoDM. Glucocorticoids were given to both groups; however, steroid-free (40.3% vs 89.6%, p = 0.020) and drug-free remission rates (40.3% vs 16.7%, p = 0.020) were higher in JDM. Malignancy-associated dermatomyositis occurred only in AoDM (n = 25, 26.6%). Age at diagnosis was independently associated with both mortality (OR 1.07 per year, 95% CI 1.02–1.11) and malignancy (OR 1.05 per year, 95% CI 1.00–1.10). Conclusion JDM and AoDM are not merely age-defined variants but display distinct clinical, serological, and prognostic profiles. JDM shows calcinosis and better remission and survival, whereas AoDM is strongly associated with malignancy and higher mortality burden, highlighting the need for age‑tailored diagnostic and management strategies.
| Reference Key |
openalex_W7203824139
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Ece Aslan, Alican Karakoç, Pelin Ozturk, Aybüke Gunalp, Zeynep Torunoğlu Bek, Nergis Akay, Ümit Gül, Elif Kılıç Könte, Mehmet Yıldız, Sezgin Şahin, Kenan Barut, Serdal Uğurlu, Özgür Kasapçopur |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag455
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.